Barclays PLC Immunocore Holdings PLC Transaction History

Barclays PLC

$357 Billion
Q4 2024

A detailed history of Barclays PLC transactions in Immunocore Holdings PLC stock. As of the latest transaction made, Barclays PLC holds 20,625 shares of IMCR stock, worth $603,281. This represents 0.0% of its overall portfolio holdings.

Number of Shares

20,625

Previous 962 2043.97%

Holding current value

$603,281

Previous $30,000 1926.67%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 13, 2025	BUY	$28.14 - $34.69 $553,316 - $682,109	19,663 Added 2043.97%	20,625 $608,000
Q3 2024 Nov 15, 2024	BUY	$30.06 - $41.49 $811 - $1,120	27 Added 2.89%	962 $30,000
Q2 2024 Aug 14, 2024	SELL	$33.78 - $63.75 $230,143 - $434,328	-6,813 Reduced 87.93%	935 $32,000
Q1 2024 May 15, 2024	BUY	$60.14 - $75.36 $10,043 - $12,585	167 Added 2.2%	7,748 $503,000
Q4 2023 Feb 15, 2024	SELL	$42.85 - $69.5 $2.46 Million - $3.99 Million	-57,474 Reduced 88.35%	7,581 $518,000
Q3 2023 Nov 07, 2023	SELL	$49.5 - $66.6 $6.54 Million - $8.8 Million	-132,086 Reduced 67.0%	65,055 $3.38 Million
Q2 2023 Aug 03, 2023	SELL	$48.54 - $61.64 $283,619 - $360,162	-5,843 Reduced 2.88%	197,141 $11.8 Million
Q1 2023 May 04, 2023	BUY	$46.12 - $65.71 $270,078 - $384,797	5,856 Added 2.97%	202,984 $10 Million
Q4 2022 Feb 13, 2023	BUY	$45.51 - $65.08 $8.94 Million - $12.8 Million	196,456 Added 29234.52%	197,128 $11.3 Million
Q3 2022 Nov 03, 2022	SELL	$37.34 - $57.44 $3,883 - $5,973	-104 Reduced 13.4%	672 $32,000
Q2 2022 Aug 12, 2022	SELL	$25.46 - $37.72 $8,452 - $12,523	-332 Reduced 29.96%	776 $29,000
Q1 2022 May 16, 2022	BUY	$18.94 - $34.29 $20,985 - $37,993	1,108 New	1,108 $33,000

Others Institutions Holding IMCR

# of Institutions

125

Shares Held

42.5M

Call Options Held

79.9K

Put Options Held

46.2K

View Full List

About Immunocore Holdings plc

Ticker IMCR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,897,100
Market Cap $1.28B
Description
Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. Its other programs for oncology comprise IMC-C103C that is in ...

More about IMCR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account